39.64
0.13%
-0.05
After Hours:
39.64
QuidelOrtho Corporation stock is currently priced at $39.64, with a 24-hour trading volume of 545.95K.
It has seen a -0.13% decreased in the last 24 hours and a -15.66% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $39.78 pivot point. If it approaches the $38.82 support level, significant changes may occur.
Previous Close:
$39.69
Open:
$39.49
24h Volume:
545.95K
Market Cap:
$2.65B
Revenue:
$3.00B
Net Income/Loss:
$-10.10M
P/E Ratio:
208.63
EPS:
0.19
Net Cash Flow:
$70.90M
1W Performance:
+1.33%
1M Performance:
-15.66%
6M Performance:
-36.41%
1Y Performance:
-55.29%
QuidelOrtho Corporation Stock (QDEL) Company Profile
Name
QuidelOrtho Corporation
Sector
Industry
Phone
858-552-1100
Address
12544 High Bluff Drive, Suite 200, San Diego, CA
QuidelOrtho Corporation Stock (QDEL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Oct-14-22 | Upgrade | UBS | Sell → Neutral |
Sep-19-22 | Initiated | Citigroup | Neutral |
Jul-20-22 | Initiated | UBS | Sell |
Jun-17-22 | Resumed | JP Morgan | Neutral |
Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
Oct-23-18 | Resumed | Raymond James | Strong Buy |
Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
Jan-22-18 | Reiterated | Barclays | Overweight |
Jan-04-18 | Upgrade | CL King | Neutral → Buy |
Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
Feb-17-17 | Initiated | CL King | Neutral |
Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
Feb-18-16 | Reiterated | Barclays | Overweight |
Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Sep-02-15 | Initiated | Barclays | Overweight |
Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
QuidelOrtho Corporation Stock (QDEL) Latest News
QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing
Zacks Investment Research
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
Zacks Investment Research
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
What's Going With COVID-19 Test Maker QuidelOrtho Stock On Tuesday?
Benzinga
2 Undervalued Mid-Cap Stocks to Own Amid Growing Rate Uncertainty
Investing.com
QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis
Zacks Investment Research
QuidelOrtho Corporation Stock (QDEL) Financials Data
QuidelOrtho Corporation (QDEL) Revenue 2024
QDEL reported a revenue (TTM) of $3.00 billion for the quarter ending December 31, 2023, a -8.21% decline year-over-year.
QuidelOrtho Corporation (QDEL) Net Income 2024
QDEL net income (TTM) was -$10.10 million for the quarter ending December 31, 2023, a -101.84% decrease year-over-year.
QuidelOrtho Corporation (QDEL) Cash Flow 2024
QDEL recorded a free cash flow (TTM) of $70.90 million for the quarter ending December 31, 2023, a -90.48% decrease year-over-year.
QuidelOrtho Corporation (QDEL) Earnings per Share 2024
QDEL earnings per share (TTM) was -$0.16 for the quarter ending December 31, 2023, a -101.29% decline year-over-year.
About QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):